Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QR9 | ISIN: FR0012616852 | Ticker: 609
Stuttgart
16.11.26 | 17:32
1,612 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABIONYX PHARMA SA Chart 1 Jahr
5-Tage-Chart
ABIONYX PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,5721,67416.11.
1,6121,65816.11.

Aktuelle News zur ABIONYX PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.11.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital273Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
04.11.ABIONYX Pharma Signs a Strategic Partnership with Lille University Hospital-Burn Treatment Center and Intensive Care Unit-to Explore the Potential of CER-001 in Severe Burn Patients at High Risk for Sepsis405Patients with severe burns and those in intensive care and resuscitation: populations at very high risk of sepsis and multi-organ failure, at the heart of the continuum between severe acute inflammation...
► Artikel lesen
ABIONYX PHARMA Aktie jetzt für 0€ handeln
27.10.ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization485An end-to-end manufacturing process for the purification of recombinant human apoA-I has now been finalized with AXPLORA A decisive step toward potential first-in-class commercialization...
► Artikel lesen
07.10.Abionyx, Olon Partner to Develop and Commercialize Sepsis Treatment4
07.10.ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply420CER-001: a distinctive manufacturing challenge to produce a full-length recombinant human apoA-I, a 243-amino-acid protein to form a biomimetic HDL particle A strategic partnership including...
► Artikel lesen
02.10.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital596Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
02.10.ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement614Anticipated amortization payment of EUR 1.75 million in principal under the Bonds financing EUR 0.52 million settled through the issuance of 331,299 new ordinary shares to Fenja Capital...
► Artikel lesen
23.09.ABIONYX Pharma: Half Year Results 2026545Cash balance of €26.9 million as of June 30, 2026, before tax credits and grants under the France 2030 plan Focus on strategy execution and rigorous program implementation in LCAT...
► Artikel lesen
10.09.ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics 637Preparation of validation batches for the CER-001 bioproduction process based on viral safety studies A key step in the industrial and regulatory dossier toward a future market launch for...
► Artikel lesen
10.09.ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma721• Selection of ABL Diagnostics' TEXCELL division for CER-001 viral safety and clearance studies • Support for a key stage of ABIONYX Pharma's industrial and regulatory program • Confirmation...
► Artikel lesen
07.09.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital558Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
27.08.ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026655Consolidated revenue of €1.9 million as of the end of June 2026 Cash balance of €26.9 million as of June 30, 2026 prior to receiving Research Tax Credits and grants under the France 2030...
► Artikel lesen
04.08.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital470Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
06.07.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital526Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
06.07.ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA992Regulatory News: Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account...
► Artikel lesen
30.06.ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis665All resolutions submitted for a vote at today's Combined General Meeting were approved Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide...
► Artikel lesen
18.06.ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M1.036Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share Drawdown of the First Tranche...
► Artikel lesen
09.06.ABIONYX Pharma: Combined Annual Shareholders' Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting492Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary...
► Artikel lesen
02.06.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital480Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
29.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026598Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded...
► Artikel lesen
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1